Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
T Acute Lymphoblastic Leukemia
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Leukemia (1944
)
Acute Myelogenous Leukemia (902
)
Acute Lymphocytic Leukemia (389
)
Chronic Lymphocytic Leukemia (292
)
Chronic Myeloid Leukemia (255
)
B Acute Lymphoblastic Leukemia (163
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Hairy Cell Leukemia (19
)
Chronic Myelomonocytic Leukemia (18
)
Prolymphocytic Leukemia (16
)
Acute Promyelocytic Leukemia (12
)
Chronic Eosinophilic Leukemia (4
)
Juvenile Myelomonocytic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
Leukemia (1944
)
Acute Myelogenous Leukemia (902
)
Acute Lymphocytic Leukemia (389
)
Chronic Lymphocytic Leukemia (292
)
Chronic Myeloid Leukemia (255
)
B Acute Lymphoblastic Leukemia (163
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Hairy Cell Leukemia (19
)
Chronic Myelomonocytic Leukemia (18
)
Prolymphocytic Leukemia (16
)
Acute Promyelocytic Leukemia (12
)
Chronic Eosinophilic Leukemia (4
)
Juvenile Myelomonocytic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
›
Associations
(38)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
No biomarker
T Acute Lymphoblastic Leukemia
No biomarker
T Acute Lymphoblastic Leukemia
nelarabine
Sensitive: A1 - Approval
Businesswire - 3 weeks (New A1)
nelarabine
Sensitive
:
A1
Businesswire - 3wk
nelarabine
Sensitive: A1 - Approval
Businesswire - 3 weeks
nelarabine
Sensitive
:
A1
Businesswire - 3 weeks - (New A1)
No biomarker
T Acute Lymphoblastic Leukemia
No biomarker
T Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
No biomarker
T Acute Lymphoblastic Leukemia
No biomarker
T Acute Lymphoblastic Leukemia
vincristine + prednisone + daunorubicin + pegaspargase + nelarabine
Sensitive: A2 - Guideline
vincristine + prednisone + daunorubicin + pegaspargase + nelarabine
Sensitive
:
A2
vincristine + prednisone + daunorubicin + pegaspargase + nelarabine
Sensitive: A2 - Guideline
vincristine + prednisone + daunorubicin + pegaspargase + nelarabine
Sensitive
:
A2
TP53 mutation
T Acute Lymphoblastic Leukemia
TP53 mutation
T Acute Lymphoblastic Leukemia
venetoclax
Sensitive: C1 - Off-label
venetoclax
Sensitive
:
C1
venetoclax
Sensitive: C1 - Off-label
venetoclax
Sensitive
:
C1
NOTCH1 mutation
T Acute Lymphoblastic Leukemia
NOTCH1 mutation
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
FBXW7 mutation
T Acute Lymphoblastic Leukemia
FBXW7 mutation
T Acute Lymphoblastic Leukemia
prednisone
Resistant: C3 – Early Trials
prednisone
Resistant
:
C3
prednisone
Resistant: C3 – Early Trials
prednisone
Resistant
:
C3
HGF-L
T Acute Lymphoblastic Leukemia
HGF-L
T Acute Lymphoblastic Leukemia
mogamulizumab
Resistant: C3 – Early Trials
mogamulizumab
Resistant
:
C3
mogamulizumab
Resistant: C3 – Early Trials
mogamulizumab
Resistant
:
C3
NOTCH1 L1574Q
T Acute Lymphoblastic Leukemia
NOTCH1 L1574Q
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
NOTCH1 V1577E
T Acute Lymphoblastic Leukemia
NOTCH1 V1577E
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
NOTCH1 L1600Q
T Acute Lymphoblastic Leukemia
NOTCH1 L1600Q
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
NOTCH1 L1585R
T Acute Lymphoblastic Leukemia
NOTCH1 L1585R
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
NOTCH1 V1577A
T Acute Lymphoblastic Leukemia
NOTCH1 V1577A
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
NOTCH1 L1600P
T Acute Lymphoblastic Leukemia
NOTCH1 L1600P
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
NOTCH1 L1574P
T Acute Lymphoblastic Leukemia
NOTCH1 L1574P
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
NOTCH1 F1592S
T Acute Lymphoblastic Leukemia
NOTCH1 F1592S
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
NOTCH1 F1592C
T Acute Lymphoblastic Leukemia
NOTCH1 F1592C
T Acute Lymphoblastic Leukemia
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
prednisone
Sensitive: C3 – Early Trials
prednisone
Sensitive
:
C3
JAK3 mutation
T Acute Lymphoblastic Leukemia
JAK3 mutation
T Acute Lymphoblastic Leukemia
tofacitinib
Resistant: C4 – Case Studies
tofacitinib
Resistant
:
C4
tofacitinib
Resistant: C4 – Case Studies
tofacitinib
Resistant
:
C4
SET-NUP214 fusion
T Acute Lymphoblastic Leukemia
SET-NUP214 fusion
T Acute Lymphoblastic Leukemia
ADE
Sensitive: C4 – Case Studies
ADE
Sensitive
:
C4
ADE
Sensitive: C4 – Case Studies
ADE
Sensitive
:
C4
FGFR1 rearrangement + Chr t(8;13)
T Acute Lymphoblastic Leukemia
FGFR1 rearrangement + Chr t(8;13)
T Acute Lymphoblastic Leukemia
Tyrosine kinase inhibitor
Resistant: C4 – Case Studies
Tyrosine kinase inhibitor
Resistant
:
C4
Tyrosine kinase inhibitor
Resistant: C4 – Case Studies
Tyrosine kinase inhibitor
Resistant
:
C4
TP53 mutation
T Acute Lymphoblastic Leukemia
TP53 mutation
T Acute Lymphoblastic Leukemia
CD7-targeted CAR-T immunotherapy
Sensitive: C4 – Case Studies
CD7-targeted CAR-T immunotherapy
Sensitive
:
C4
CD7-targeted CAR-T immunotherapy
Sensitive: C4 – Case Studies
CD7-targeted CAR-T immunotherapy
Sensitive
:
C4
MEF2C overexpression
T Acute Lymphoblastic Leukemia
MEF2C overexpression
T Acute Lymphoblastic Leukemia
ABT-737
Sensitive: D – Preclinical
ABT-737
Sensitive
:
D
ABT-737
Sensitive: D – Preclinical
ABT-737
Sensitive
:
D
PAK2 overexpression
T Acute Lymphoblastic Leukemia
PAK2 overexpression
T Acute Lymphoblastic Leukemia
FRAX597 + PF-3758309
Sensitive: D – Preclinical
FRAX597 + PF-3758309
Sensitive
:
D
FRAX597 + PF-3758309
Sensitive: D – Preclinical
FRAX597 + PF-3758309
Sensitive
:
D
MCL1 underexpression
T Acute Lymphoblastic Leukemia
MCL1 underexpression
T Acute Lymphoblastic Leukemia
venetoclax + NBL-001
Sensitive: D – Preclinical
venetoclax + NBL-001
Sensitive
:
D
venetoclax + NBL-001
Sensitive: D – Preclinical
venetoclax + NBL-001
Sensitive
:
D
MYC underexpression
T Acute Lymphoblastic Leukemia
MYC underexpression
T Acute Lymphoblastic Leukemia
venetoclax + NBL-001
Sensitive: D – Preclinical
venetoclax + NBL-001
Sensitive
:
D
venetoclax + NBL-001
Sensitive: D – Preclinical
venetoclax + NBL-001
Sensitive
:
D
CCND3 deletion
T Acute Lymphoblastic Leukemia
CCND3 deletion
T Acute Lymphoblastic Leukemia
palbociclib
Sensitive: D – Preclinical
palbociclib
Sensitive
:
D
palbociclib
Sensitive: D – Preclinical
palbociclib
Sensitive
:
D
JAK3 M511I
T Acute Lymphoblastic Leukemia
JAK3 M511I
T Acute Lymphoblastic Leukemia
tofacitinib XR
Sensitive: D – Preclinical
tofacitinib XR
Sensitive
:
D
tofacitinib XR
Sensitive: D – Preclinical
tofacitinib XR
Sensitive
:
D
JAK3 M511I
T Acute Lymphoblastic Leukemia
JAK3 M511I
T Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: D – Preclinical
ruxolitinib
Sensitive
:
D
ruxolitinib
Sensitive: D – Preclinical
ruxolitinib
Sensitive
:
D
NOTCH1 mutation
T Acute Lymphoblastic Leukemia
NOTCH1 mutation
T Acute Lymphoblastic Leukemia
CB-839
Sensitive: D – Preclinical
CB-839
Sensitive
:
D
CB-839
Sensitive: D – Preclinical
CB-839
Sensitive
:
D
NOTCH1 mutation
T Acute Lymphoblastic Leukemia
NOTCH1 mutation
T Acute Lymphoblastic Leukemia
IACS-010759
Sensitive: D – Preclinical
IACS-010759
Sensitive
:
D
IACS-010759
Sensitive: D – Preclinical
IACS-010759
Sensitive
:
D
BCL2L1 underexpression
T Acute Lymphoblastic Leukemia
BCL2L1 underexpression
T Acute Lymphoblastic Leukemia
venetoclax + NBL-001
Sensitive: D – Preclinical
venetoclax + NBL-001
Sensitive
:
D
venetoclax + NBL-001
Sensitive: D – Preclinical
venetoclax + NBL-001
Sensitive
:
D
PRC2 mutation
T Acute Lymphoblastic Leukemia
PRC2 mutation
T Acute Lymphoblastic Leukemia
JQ-1
Sensitive: D – Preclinical
JQ-1
Sensitive
:
D
JQ-1
Sensitive: D – Preclinical
JQ-1
Sensitive
:
D
PCDHB15 overexpression
T Acute Lymphoblastic Leukemia
PCDHB15 overexpression
T Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: D – Preclinical
ruxolitinib
Sensitive
:
D
ruxolitinib
Sensitive: D – Preclinical
ruxolitinib
Sensitive
:
D
NUP214-ABL1 rearrangement
T Acute Lymphoblastic Leukemia
NUP214-ABL1 rearrangement
T Acute Lymphoblastic Leukemia
dasatinib
Sensitive: D – Preclinical
dasatinib
Sensitive
:
D
dasatinib
Sensitive: D – Preclinical
dasatinib
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login